China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2025)

China SXT Pharmaceuticals' Receivables - Net history runs 8 years deep, the most recent figure standing at $1.3 million for Q3 2025.

• In Q3 2025, Receivables - Net fell 19.7% year-over-year to $1.3 million; the TTM figure through Sep 2025 stood at $1.3 million (down 19.7% YoY), while the FY2025 annual figure was $3.4 million, up 11.08% from the prior year.
• Receivables - Net was $1.3 million for Q3 2025 at China SXT Pharmaceuticals, up from $1.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $4.5 million in Q1 2021 to a low of $1.3 million in Q1 2025.
• Historically, Receivables - Net has averaged $2.7 million across 5 years, with a median of $3.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net plunged 60.55% in 2023, then increased 26.93% in 2024.
• A 5-year view of Receivables - Net shows it stood at $3.9 million in 2021, then slipped by 14.42% to $3.3 million in 2022, then slumped by 60.55% to $1.3 million in 2023, then climbed by 26.93% to $1.7 million in 2024, then decreased by 19.7% to $1.3 million in 2025.
• The last three Receivables - Net figures came in at $1.3 million (Q3 2025), $1.3 million (Q1 2025), and $1.7 million (Q3 2024), per Business Quant data.